YD Life Science acquires approval of DR therapy for Phase 2a clinical trial in U.S.

Published: 2018-08-23 16:26:00
Updated: 2018-08-23 17:18:34

YD Life Science(CEO Jin-Woo Lee) announced on the 21st that its diabetic retinopathy(DR) therapy ‘YD-312’ acquired final approval for a Phase 2a clinical trial from the U.S. Food and Drug Administration.

Diabetic retinopathy, a diabetes complication, is a dermatologic disease which affects eyes....


- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean

Most Read News

Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.